腹腔热灌注化疗治疗卵巢癌 60例

目的 观察腹腔热灌注化疗治疗晚期卵巢癌的临床效果.方法 选取2015年4月至2018年4月在黄河三门峡医院接受治疗的卵巢癌病人120例,对其进行卵巢癌肿瘤细胞减灭术,术后采用随机数字表法分为观察组和对照组,各60例,对照组给予静脉化疗,观察组给予腹腔热灌注化疗联合静脉化疗,比较两组治疗后的肿瘤标志物CA125、CA199、CA153、甲胎蛋白(AFP)、癌胚抗原(CEA)、人附睾蛋白4(HE4)的情况,比较两组治疗后1年、2年复发率及生存率.结果 观察组与对照组比较,观察组CA125(1个月52例比40例,3个月58例比44例)、CA199(1个月27例比14例,3个月32例比20例)、CA153(1个月40例比32例,3个月50例比38例)、AFP(1个月10例比8例,3个月16例比12例)、CEA(1个月12例比10例,3个月18例比14例)、HE4(1个月49例比34例,3个月58例比38例)在1个月、3个月时降至正常的例数高于对照组(P<0.05),观察组的1年(63.33％比75.00％)、2年的复发率(88.33％比95.00％)低于对照组,观察组的1年(86.67％比76.67％)、2年生存率(63.33％比50.00％)高于对照组.结论 晚期卵巢癌病人在手术后进行热灌注化疗联合静脉化疗,对控制肿瘤的生长有明显作用,复发率更低,生存率更高,值得在临床工作中进一步开展与应用.

Treatment of ovarian cancer with hyperthermic intraperitoneal chemotherapy: 60 cases

Objective To investigate the clinical efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced ovarian cancer.Methods A total of 120 patients with ovarian cancer who were treated in Yellow River Sanmenxia Hospitalfrom April 2015 to April 2018 were enrolled and treated with ovarian cancer tumor suppressant surgery. After surgery, they were randomly divided into two groups. The control group received intravenous chemotherapy. The observation group received hyperthermic intraperitoneal chemotherapy combined with intravenous chemotherapy. The tumor markers CA125, CA199, CA153, AFP, CEA, HE4 after treatment, relapse rate and survival rate after 1 year and 2 years of treatment in the two groups of patients were compared.Results The number of cases in which CA125 (1 month 52 cases vs. 40 cases,3 month 58 cases vs. 44 cases),CA199 (1 month 27 cases vs. 14 cases,3 month 32 cases vs. 20 cases),CA153 (1 month 40 cases vs. 32 cases,3 month 50 cases vs. 38 cases),AFP (1 month10 cases vs.8 cases,3 month 16 cases vs. 12 cases),CEA (1 month 12 cases vs. 10 cases,3 month 18 cases vs. 14 cases), HE4 (1 month 49 cases vs. 34 cases,3 month 58 cases vs. 38 cases) were reduced to normal at 1 month and 3 months in the observation group was higher than in the control group. (P<0.05) .The recurrence rate for 1 year (63.33% vs. 75.00%) and 2 years (88.33% vs. 95.00%) in the observation group was lower than that of the control group, and the survival rate for 1 year (86.67% vs. 76.67%) and 2 years (63.33% vs. 50.00%) in the observation group was higher than that of the control group.Conclusion Hyperthermic intraperitoneal chemotherapy combined withintravenous chemotherapy in patients with advanced ovarian cancer after surgery has a significant effect on controlling the growth of thetumor, with lower recurrence rate and higher survival rate, which is worthy of further development and application in clinical work.